Ptc Therapeutics, Inc. (PTCT): who owns it and who trades it
As of Nov 16, 2026, PTCT insiders reported 202 open-market sales worth $56.2M and no purchases in the last 12 months, with 100% of the sale value made under pre-set 10b5-1 plans. The largest seller was Neil Gregory Almstead (CHIEF TECHNICAL OPS OFFI), with $22.4M. 7 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling PTC Therapeutics
From the latest filingsOverall: more buying than selling. Famous investors mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns PTCT
380 funds and institutions reported PTCT shares worth $8.2B at the end of Q2 2026. The largest holder is BlackRock, Inc. with $1.1B.
10 largest owners, by value
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 13.96M | – | $1.1B | +8% |
| Rtw Investments, LP | 7.75M | – | $632M | No change |
| Jupiter Topco LLC | 7.24M | – | $590M | – |
| Vanguard Portfolio Management LLC | 4.93M | – | $402M | +3% |
| State Street Corp | 4.60M | – | $375M | +6% |
| Wellington Management Group LLP | 4.13M | – | $337M | +5% |
| Vanguard Capital Management LLC | 3.74M | – | $305M | +2% |
| Geode Capital Management, LLC | 2.21M | – | $180M | -0% |
| Toronto Dominion Bank | 2.17M | – | $177M | -28% |
| Westfield Capital Management Co LP | 1.96M | – | $160M | – |
| Hood River Capital Management LLC | 1.74M | – | $142M | +4% |
| William Blair Investment Management, LLC | 1.72M | – | $141M | – |
| D. E. Shaw & Co., Inc. | 1.55M | – | $126M | -6% |
| Tang Capital Management LLC | 1.50M | – | $122M | No change |
| Bank of America Corp | 1.45M | – | $118M | -23% |
| Driehaus Capital Management LLC | 1.44M | – | $117M | +42% |
| FMR LLC (Fidelity) | 1.40M | – | $114M | -9% |
| Jefferies Financial Group Inc. | 1.36M | – | $111M | +0% |
| Fuller & Thaler Asset Management, Inc. | 1.16M | – | $94.4M | – |
| Pictet Asset Management Holding SA | 1.15M | – | $93.6M | -3% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, PTCT insiders reported $0 of open-market purchases and $56.2M of sales. 100% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 14, 2026 | Michael Schmertzler | Director | Sale plan | 2,118 | $59.52 | $126K | Form 4 |
| Oct 14, 2026 | Michael Schmertzler | Director | Sale plan | 382 | $60.14 | $23K | Form 4 |
| Oct 9, 2026 | Mark Elliott Boulding | Vice president | Sale plan | 192 | $64.26 | $12.3K | Form 4 |
| Oct 7, 2026 | Michael Schmertzler | Director | Sale plan | 2,447 | $63.38 | $155K | Form 4 |
| Oct 7, 2026 | Michael Schmertzler | Director | Sale plan | 53 | $63.95 | $3.4K | Form 4 |
| Oct 6, 2026 | Mark Elliott Boulding | Vice president | Sale plan | 435 | $64.16 | $27.9K | Form 4 |
| Oct 5, 2026 | Mark Elliott Boulding | Vice president | Sale plan | 1,638 | $64.03 | $105K | Form 4 |
| Sep 30, 2026 | Glenn Jr Md Phd Steele | Director | Sale plan | 12,000 | $65.16 | $782K | Form 4 |
| Sep 17, 2026 | Michael Schmertzler | Director | Sale plan | 376 | $68.45 | $25.7K | Form 4 |
| Sep 17, 2026 | Michael Schmertzler | Director | Sale plan | 9,624 | $67.83 | $653K | Form 4 |
| Sep 16, 2026 | Michael Schmertzler | Director | Sale plan | 2,994 | $66.58 | $199K | Form 4 |
| Sep 16, 2026 | Michael Schmertzler | Director | Sale plan | 7,006 | $67.35 | $472K | Form 4 |
| Sep 10, 2026 | Michael Schmertzler | Director | Sale plan | 10,000 | $67.34 | $673K | Form 4 |
| Sep 9, 2026 | Michael Schmertzler | Director | Sale plan | 9,428 | $67.79 | $639K | Form 4 |
| Sep 9, 2026 | Michael Schmertzler | Director | Sale plan | 572 | $68.67 | $39.3K | Form 4 |
| Aug 27, 2026 | Michael Schmertzler | Director | Sale plan | 610 | $72.22 | $44.1K | Form 4 |
| Aug 27, 2026 | Michael Schmertzler | Director | Sale plan | 11,890 | $71.55 | $851K | Form 4 |
| Aug 26, 2026 | Michael Schmertzler | Director | Sale plan | 6,874 | $72.74 | $500K | Form 4 |
| Aug 26, 2026 | Michael Schmertzler | Director | Sale plan | 5,626 | $73.18 | $412K | Form 4 |
| Aug 20, 2026 | Michael Schmertzler | Director | Sale plan | 691 | $72.92 | $50.4K | Form 4 |
| Aug 20, 2026 | Michael Schmertzler | Director | Sale plan | 2,390 | $71.88 | $172K | Form 4 |
| Aug 20, 2026 | Michael Schmertzler | Director | Sale plan | 9,419 | $70.78 | $667K | Form 4 |
| Aug 19, 2026 | Michael Schmertzler | Director | Sale plan | 5,335 | $72.86 | $389K | Form 4 |
| Aug 19, 2026 | Michael Schmertzler | Director | Sale plan | 7,165 | $73.67 | $528K | Form 4 |
| Aug 17, 2026 | Mark Elliott Boulding | Vice president | Sale plan | 969 | $72.90 | $70.6K | Form 4 |
| Aug 17, 2026 | Mark Elliott Boulding | Vice president | Sale plan | 1,844 | $72.39 | $133K | Form 4 |
| Aug 4, 2026 | Matthew B. Klein | CEO | Sale plan | 10,292 | $68.57 | $706K | Form 4 |
| Jul 14, 2026 | Pierre Gravier | CFO | Sale plan | 3,494 | $80.35 | $281K | Form 4 |
| Jul 9, 2026 | Mary L. Smith | Director | Sale plan | 5,834 | $90.00 | $525K | Form 4 |
| Jul 9, 2026 | Mary L. Smith | Director | Sale plan | 10,000 | $90.00 | $900K | Form 4 |
| Jul 9, 2026 | Neil Gregory Almstead | CHIEF TECHNICAL OPS OFFI | Sale plan | 2,464 | $90.25 | $222K | Form 4 |
| Jul 7, 2026 | Neil Gregory Almstead | CHIEF TECHNICAL OPS OFFI | Sale plan | 9,288 | $89.44 | $831K | Form 4 |
| Jul 7, 2026 | Neil Gregory Almstead | CHIEF TECHNICAL OPS OFFI | Sale plan | 11,369 | $89.03 | $1M | Form 4 |
| Jul 7, 2026 | Neil Gregory Almstead | CHIEF TECHNICAL OPS OFFI | Sale plan | 3,956 | $87.17 | $345K | Form 4 |
| Jul 6, 2026 | Mark Elliott Boulding | Vice president | Sale plan | 833 | $84.41 | $70.3K | Form 4 |
| Jul 6, 2026 | Mark Elliott Boulding | Vice president | Sale plan | 313 | $83.10 | $26K | Form 4 |
| Jul 6, 2026 | Mark Elliott Boulding | Vice president | Sale plan | 745 | $86.38 | $64.4K | Form 4 |
| Jul 6, 2026 | Mark Elliott Boulding | Vice president | Sale plan | 519 | $85.84 | $44.6K | Form 4 |
| Jul 6, 2026 | Mark Elliott Boulding | Vice president | Sale plan | 1,036 | $84.41 | $87.4K | Form 4 |
| Jul 6, 2026 | Mark Elliott Boulding | Vice president | Sale plan | 387 | $83.10 | $32.2K | Form 4 |
| Jul 6, 2026 | Mark Elliott Boulding | Vice president | Sale plan | 601 | $86.38 | $51.9K | Form 4 |
| Jul 6, 2026 | Mark Elliott Boulding | Vice president | Sale plan | 645 | $85.84 | $55.4K | Form 4 |
| Jul 6, 2026 | Neil Gregory Almstead | CHIEF TECHNICAL OPS OFFI | Sale plan | 385 | $86.34 | $33.2K | Form 4 |
| Jul 6, 2026 | Neil Gregory Almstead | CHIEF TECHNICAL OPS OFFI | Sale plan | 426 | $85.28 | $36.3K | Form 4 |
| Jul 6, 2026 | Neil Gregory Almstead | CHIEF TECHNICAL OPS OFFI | Sale plan | 2,474 | $87.03 | $215K | Form 4 |
| Jul 6, 2026 | Neil Gregory Almstead | CHIEF TECHNICAL OPS OFFI | Sale plan | 8,786 | $85.35 | $750K | Form 4 |
| Jul 6, 2026 | Neil Gregory Almstead | CHIEF TECHNICAL OPS OFFI | Sale plan | 10,090 | $86.32 | $871K | Form 4 |
| Jun 26, 2026 | Neil Gregory Almstead | CHIEF TECHNICAL OPS OFFI | Sale plan | 412 | $85.23 | $35.1K | Form 4 |
| Jun 26, 2026 | Neil Gregory Almstead | CHIEF TECHNICAL OPS OFFI | Sale plan | 7,718 | $85.26 | $658K | Form 4 |
| Jun 25, 2026 | Neil Gregory Almstead | CHIEF TECHNICAL OPS OFFI | Sale plan | 419 | $86.39 | $36.2K | Form 4 |
| Jun 25, 2026 | Neil Gregory Almstead | CHIEF TECHNICAL OPS OFFI | Sale plan | 8,522 | $85.26 | $727K | Form 4 |
| Jun 25, 2026 | Neil Gregory Almstead | CHIEF TECHNICAL OPS OFFI | Sale plan | 11,337 | $86.51 | $981K | Form 4 |
| Jun 25, 2026 | Neil Gregory Almstead | CHIEF TECHNICAL OPS OFFI | Sale plan | 100 | $87.00 | $8.7K | Form 4 |
| Jun 25, 2026 | Neil Gregory Almstead | CHIEF TECHNICAL OPS OFFI | Sale plan | 582 | $85.24 | $49.6K | Form 4 |
| Jun 24, 2026 | Neil Gregory Almstead | CHIEF TECHNICAL OPS OFFI | Sale plan | 401 | $85.01 | $34.1K | Form 4 |
| Jun 24, 2026 | Neil Gregory Almstead | CHIEF TECHNICAL OPS OFFI | Sale plan | 4,922 | $85.03 | $419K | Form 4 |
| Jun 22, 2026 | Neil Gregory Almstead | CHIEF TECHNICAL OPS OFFI | Sale plan | 11,619 | $81.21 | $944K | Form 4 |
| Jun 22, 2026 | Neil Gregory Almstead | CHIEF TECHNICAL OPS OFFI | Sale plan | 12,130 | $80.61 | $978K | Form 4 |
| Jun 17, 2026 | Christine Marie Utter | Vice president | Sale plan | 19,686 | $75.56 | $1.5M | Form 4 |
| Jun 17, 2026 | Mark Elliott Boulding | Vice president | Sale plan | 1,850 | $79.24 | $147K | Form 4 |
| Jun 17, 2026 | Mark Elliott Boulding | Vice president | Sale plan | 1,703 | $78.50 | $134K | Form 4 |
| Jun 17, 2026 | Mark Elliott Boulding | Vice president | Sale plan | 309 | $79.25 | $24.5K | Form 4 |
| Jun 17, 2026 | Mark Elliott Boulding | Vice president | Sale plan | 6,600 | $78.50 | $518K | Form 4 |
| Jun 10, 2026 | Eric Pauwels | CHIEF BUSINESS OFFICER | Sale plan | 3,711 | $75.00 | $278K | Form 4 |
| Jun 10, 2026 | Eric Pauwels | CHIEF BUSINESS OFFICER | Sale plan | 17,566 | $75.00 | $1.3M | Form 4 |
| May 15, 2026 | Mark Elliott Boulding | Vice president | Sale plan | 456 | $72.67 | $33.1K | Form 4 |
| May 15, 2026 | Mark Elliott Boulding | Vice president | Sale plan | 2,356 | $72.08 | $170K | Form 4 |
| May 14, 2026 | Matthew B. Klein | CEO | Sale plan | 7,221 | $73.08 | $528K | Form 4 |
| May 14, 2026 | Matthew B. Klein | CEO | Sale plan | 679 | $73.06 | $49.6K | Form 4 |
| May 14, 2026 | Matthew B. Klein | CEO | Sale plan | 2,100 | $73.08 | $153K | Form 4 |
| May 14, 2026 | Matthew B. Klein | CEO | Sale plan | 2,572 | $72.46 | $186K | Form 4 |
| May 8, 2026 | Mark Elliott Boulding | Vice president | Sale plan | 840 | $78.23 | $65.7K | Form 4 |
| May 8, 2026 | Mark Elliott Boulding | Vice president | Sale plan | 1,900 | $79.31 | $151K | Form 4 |
| May 8, 2026 | Mark Elliott Boulding | Vice president | Sale plan | 200 | $78.00 | $15.6K | Form 4 |
| May 8, 2026 | Mark Elliott Boulding | Vice president | Sale plan | 600 | $79.28 | $47.6K | Form 4 |
| Apr 21, 2026 | Matthew B. Klein | CEO | Sale plan | 2,850 | $70.91 | $202K | Form 4 |
| Apr 6, 2026 | Mark Elliott Boulding | Vice president | Sale plan | 822 | $68.91 | $56.6K | Form 4 |
| Apr 6, 2026 | Mark Elliott Boulding | Vice president | Sale plan | 1,443 | $69.75 | $101K | Form 4 |
| Apr 2, 2026 | Lee Scott Golden | Vice president | Sale plan | 829 | $67.99 | $56.4K | Form 4 |
| Apr 1, 2026 | Neil Gregory Almstead | CHIEF TECHNICAL OPS OFFI | Sale plan | 39,393 | $68.89 | $2.7M | Form 4 |
| Apr 1, 2026 | Neil Gregory Almstead | CHIEF TECHNICAL OPS OFFI | Sale plan | 80 | $70.30 | $5.6K | Form 4 |
| Apr 1, 2026 | Neil Gregory Almstead | CHIEF TECHNICAL OPS OFFI | Sale plan | 12,530 | $69.50 | $871K | Form 4 |
| Mar 12, 2026 | Matthew B. Klein | CEO | Sale plan | 2,662 | $64.08 | $171K | Form 4 |
| Mar 10, 2026 | Stephanie Okey | Director | Sale plan | 1,167 | $70.00 | $81.7K | Form 4 |
| Mar 10, 2026 | Stephanie Okey | Director | Sale plan | 14,000 | $70.00 | $980K | Form 4 |
| Mar 5, 2026 | Stephanie Okey | Director | Sale plan | 6,333 | $63.38 | $401K | Form 4 |
| Mar 5, 2026 | Lee Scott Golden | Vice president | Sale plan | 10,000 | $63.38 | $634K | Form 4 |
| Mar 5, 2026 | Neil Gregory Almstead | CHIEF TECHNICAL OPS OFFI | Sale plan | 3,989 | $63.38 | $253K | Form 4 |
| Feb 19, 2026 | Mark Elliott Boulding | Vice president | Sale plan | 590 | $69.82 | $41.2K | Form 4 |
| Feb 19, 2026 | Mark Elliott Boulding | Vice president | Sale plan | 212 | $68.54 | $14.5K | Form 4 |
| Feb 19, 2026 | Mark Elliott Boulding | Vice president | Sale plan | 1,629 | $69.82 | $114K | Form 4 |
| Feb 19, 2026 | Mark Elliott Boulding | Vice president | Sale plan | 588 | $68.54 | $40.3K | Form 4 |
| Feb 18, 2026 | Christine Marie Utter | Vice president | Sale plan | 2,494 | $69.36 | $173K | Form 4 |
| Feb 18, 2026 | Pierre Gravier | CFO | Sale plan | 2,992 | $69.36 | $208K | Form 4 |
| Feb 18, 2026 | Eric Pauwels | CHIEF BUSINESS OFFICER | Sale plan | 3,019 | $69.36 | $209K | Form 4 |
| Feb 18, 2026 | Matthew B. Klein | CEO | Sale plan | 7,371 | $69.36 | $511K | Form 4 |
| Feb 18, 2026 | Lee Scott Golden | Vice president | Sale plan | 2,484 | $69.36 | $172K | Form 4 |
| Feb 18, 2026 | Neil Gregory Almstead | CHIEF TECHNICAL OPS OFFI | Sale plan | 3,056 | $69.36 | $212K | Form 4 |
| Feb 18, 2026 | Neil Gregory Almstead | CHIEF TECHNICAL OPS OFFI | Sale plan | 65 | $69.36 | $4.5K | Form 4 |
| Feb 18, 2026 | Mark Elliott Boulding | Vice president | Sale plan | 3,081 | $69.36 | $214K | Form 4 |
Latest 100 of 202 trades in the last 12 months.
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Neil Gregory Almstead | CHIEF TECHNICAL OPS OFFICER | – | $22.4M | Jul 9, 2026 |
| Eric Pauwels | CHIEF BUSINESS OFFICER | – | $7.5M | Jun 10, 2026 |
| Michael Schmertzler | Director | – | $6.6M | Oct 14, 2026 |
| Mark Elliott Boulding | EXEC. VP AND CLO | – | $4.2M | Oct 9, 2026 |
| Matthew B. Klein | CHIEF EXECUTIVE OFFICER, Director | – | $4.2M | Aug 4, 2026 |
| Allan Steven Jacobson | Director | – | $2.1M | Nov 25, 2025 |
| Christine Marie Utter | SVP, CHIEF ACCOUNTING OFFICER | – | $1.9M | Jun 17, 2026 |
| Glenn Jr Md Phd Steele | Director | – | $1.7M | Sep 30, 2026 |
| Stephanie Okey | Director | – | $1.5M | Mar 10, 2026 |
| Mary L. Smith | Director | – | $1.4M | Jul 9, 2026 |
| Lee Scott Golden | EVP & CHIEF MEDICAL OFFICER | – | $1.1M | Apr 2, 2026 |
| Emma Reeve | Director | – | $908K | Jan 5, 2026 |
| Pierre Gravier | CHIEF FINANCIAL OFFICER | – | $653K | Jul 14, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
PTCT short interest
Moderate short interest. 9.3% of PTCT shares are sold short: about 1 share in 11. Over the last 12 reports the number of shares short went down 24%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 7.78M PTCT shares were sold short, 9.3% of the shares outstanding, down 6.3% from the report before. At the average daily volume of 1.04M shares, buying them all back would take about 7.5 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 7.78M | 9.31% | -6% | 1.04M | 7.5 |
| Oct 15, 2026 | 8.30M | 9.95% | -9% | 1.09M | 7.6 |
| Sep 30, 2026 | 9.17M | 10.99% | -6% | 1.49M | 6.1 |
| Sep 15, 2026 | 9.74M | 11.67% | -1% | 882,762 | 11.0 |
| Aug 31, 2026 | 9.83M | 11.78% | -4% | 809,909 | 12.1 |
| Aug 14, 2026 | 10.22M | 12.25% | -3% | 944,361 | 10.8 |
| Jul 31, 2026 | 10.57M | 12.66% | +7% | 1.40M | 7.5 |
| Jul 15, 2026 | 9.83M | – | -43% | 2.07M | 4.8 |
| Jun 30, 2026 | 17.32M | – | +47% | 3.23M | 5.4 |
| Jun 15, 2026 | 11.78M | – | +10% | 1.51M | 7.8 |
| May 29, 2026 | 10.67M | – | +4% | 963,231 | 11.1 |
| May 15, 2026 | 10.24M | – | +5% | 1.71M | 6.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
PTC Therapeutics company events
PTC Therapeutics filed 17 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Nov 3, 2026.
- Nov 3, 2026AnnouncementShared information with investors. Filing
- Oct 29, 2026ResultsReleased financial results. Filing
- Sep 21, 2026AnnouncementShared information with investors. Filing
- Aug 28, 2026AgreementPTC Therapeutics, Inc. entered into an asset purchase agreement with Sangamo Therapeutics, Inc., pursuant to which the Company agreed to acquire from Sangamo, subject to the terms and conditions set forth in the Asset Purchase Agreement, all of Sangamo ’s right, title and interest in and to the… Filing
- Aug 13, 2026AnnouncementThe Company issued a press release in which it announced the planned Acquisition. Filing
- Jul 30, 2026LeadershipThe Company appointed Hege Sollie-Zetlmayer to its board of directors, effective immediately, filling a vacancy on the Board. Filing
- Jun 18, 2026AgreementPTC Therapeutics, Inc. completed its previously announced private offering of $550 million of its 0.0% Convertible Senior Notes due 2031 and entered into an indenture with U.S. Bank Trust Company, National Association, as trustee, governing the Notes. Filing
- Jun 16, 2026AnnouncementPTC Therapeutics, Inc. issued a press release announcing the pricing of its previously announced offering of $500.0 million of 0.00% Convertible Senior Notes due 2031. Filing
- Jun 9, 2026LeadershipAlethia Young, a member of the board of directors of PTC Therapeutics, Inc., notified the Company of her resignation from the Board effective June 8, 2026. Filing
- Jun 5, 2026VoteReported shareholder vote results. Filing
- May 7, 2026ResultsReleased financial results. Filing
- Apr 28, 2026AnnouncementShared information with investors. Filing
- Mar 25, 2026LeadershipPTC Therapeutics, Inc., appointed Jessica Chutter to its board of directors, effective immediately, filling a vacancy on the Board. Filing
- Feb 19, 2026ResultsReleased financial results. Filing
- Feb 12, 2026AnnouncementShared information with investors. Filing
- Jan 12, 2026ResultsReleased financial results. Filing
- Dec 29, 2025AgreementPTC Therapeutics, Inc., Royalty Pharma Investments 2019 ICAV, and, for the limited purposes set forth in the Purchase Agreement (as defined below), Royalty Pharma plc, entered into an Amendment No. 2 to Amended and Restated Royalty Purchase Agreement, which amends that certain Amended and Restated… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
PTC Therapeutics financials
Famous investors that hold PTCT
7 of the 50 well-known investors we track reported holding PTCT in their latest 13F filing. The largest position is Steve Cohen's, worth $91.3M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Steve Cohen · Point72 Asset Management | Q3 2026 | 1.41M | $91.3M | 0.2% | New |
| Jim Simons · Renaissance Technologies | Q3 2026 | 787,100 | $51M | 0.1% | +9% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 427,252 | $27.7M | 0.0% | -43% |
| Ray Dalio · Bridgewater Associates | Q3 2026 | 145,446 | $9.4M | 0.0% | New |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 117,809 | $7.6M | 0.0% | +757% |
| Ken Fisher · Fisher Asset Management | Q3 2026 | 43,083 | $2.8M | 0.0% | +6% |
| Israel Englander · Millennium Management | Q3 2026 | 37,580 | $2.4M | 0.0% | -19% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 6 filings named PTCT in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Wellington Management Group LLP | 13G | 6.3% |
| Nov 16, 2026 | Wellington Management Group LLP | 13G | 6.3% |
| Nov 16, 2026 | RTW Investments, LP | 13G/A | 1.9% |
| Nov 16, 2026 | RTW Investments, LP | 13G/A | 1.9% |
| Nov 10, 2026 | STATE STREET CORPORATION | 13G | 6.6% |
| Nov 10, 2026 | STATE STREET CORPORATION | 13G | 6.6% |
Questions about Ptc Therapeutics, Inc. (PTCT) stock
Who owns the most PTCT stock?
The largest reported owner of Ptc Therapeutics, Inc. (PTCT) is BlackRock, Inc.. In total, 380 funds and institutions reported holding PTCT at the end of Q2 2026. See the largest owners.
Are PTCT insiders buying or selling?
In the last 12 months, PTCT insiders reported no open-market purchases and 202 sales worth $56.2M. The latest trade was on Oct 14, 2026. See every trade.
What is the short interest in PTCT?
As of Oct 30, 2026, 7.78M PTCT shares were sold short, 9.3% of the shares outstanding, down 6.3% from the report before. At the average daily volume of 1.04M shares, buying them all back would take about 7.5 trading days (days to cover). See the history.
Which famous investors hold PTCT?
7 of the 50 well-known investors we track reported PTCT in their latest 13F filing, including Steve Cohen, Jim Simons, Ken Griffin. The largest position is worth $91.3M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.